2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 624 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

  
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05286372
(ClinicalTrials.gov)
April 20229/3/2022An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAn Intermediate Size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: AMX0035Amylyx Pharmaceuticals Inc.NULLAvailable18 YearsN/AAllNULL
2EUCTR2021-000250-26-PL
(EUCTR)
23/02/202222/11/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: phenylbutyrate
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3United States;Portugal;France;Spain;Belgium;Poland;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
3EUCTR2021-000250-26-IT
(EUCTR)
14/12/202118/10/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: AMX0035
Product Code: [AMX0035]
INN or Proposed INN: Sodio phenylbutyrate
INN or Proposed INN: Tauroursodeoxycholic Acid
AMYLYX PHARMACEUTICALS Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
4EUCTR2021-000250-26-FR
(EUCTR)
22/11/202125/06/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: phenylbutyrate
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Product Code: AMX0035
INN or Proposed INN: PHENYLBUTYRATE
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Portugal;United States;France;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
5NCT05021536
(ClinicalTrials.gov)
October 28, 202120/8/2021Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisOther: Placebo;Drug: AMX0035Amylyx Pharmaceuticals Inc.NULLRecruiting18 YearsN/AAll600Phase 3United States;Puerto Rico
6EUCTR2021-000250-26-DE
(EUCTR)
27/10/202122/06/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: phenylbutyrate
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
7EUCTR2021-000250-26-ES
(EUCTR)
05/10/202123/07/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: fenilbutirato
INN or Proposed INN: Ursodoxicoltaurina
Other descriptive name: taurursodiol
Product Code: AMX0035
INN or Proposed INN: Fenilbutirato
INN or Proposed INN: Ursodoxicoltaurina
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Portugal;France;United States;Poland;Belgium;Spain;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
8EUCTR2021-000250-26-NL
(EUCTR)
03/09/202106/07/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: phenylbutyrate
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Product Code: AMX0035
INN or Proposed INN: PHENYLBUTYRATE
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Sweden;Italy;United Kingdom;Netherlands;Germany;Ireland;Belgium;Poland;Spain;United States;France;Portugal
9EUCTR2021-000250-26-SE
(EUCTR)
26/08/202128/06/2021A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix ALS (amyotrophic lateral sclerosis)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: AMX0035
INN or Proposed INN: phenylbutyrate
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Product Code: AMX0035
INN or Proposed INN: PHENYLBUTYRATE
INN or Proposed INN: Ursodoxicoltaurine
Other descriptive name: taurursodiol
Amylyx Pharmaceuticals Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden
10NCT04516096
(ClinicalTrials.gov)
November 22, 20209/8/2020A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)AMX0035 for Amyotrophic Lateral Sclerosis - Compassionate Use ProtocolAmyotrophic Lateral SclerosisDrug: AMX0035Amylyx Pharmaceuticals Inc.NULLEnrolling by invitation18 YearsN/AAll40Phase 2/Phase 3United States
11NCT03488524
(ClinicalTrials.gov)
March 29, 201823/3/2018Open Label Extension Study of AMX0035 in Patients With ALSOpen Label Extension Study of AMX0035 in Patients With ALSAmyotrophic Lateral Sclerosis;ALSDrug: AMX0035Amylyx Pharmaceuticals Inc.Massachusetts General Hospital Neurology Clinical Research InstituteCompletedN/AN/AAll95Phase 2United States
12NCT03127514
(ClinicalTrials.gov)
June 22, 201712/4/2017AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALSAmyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Diseases;Neurodegenerative Diseases;Spinal Cord Diseases;TDP-43 Proteinopathies;Nervous System Diseases;Central Nervous System DiseasesDrug: AMX0035;Other: PlaceboAmylyx Pharmaceuticals Inc.ALS Finding a Cure Foundation;ALS Association;Northeast ALS Consortium;Massachusetts General Hospital Neurology Clinical Research Institute;Leandro P. Rizzuto FoundationCompleted18 Years80 YearsAll137Phase 2/Phase 3United States